Please try another search
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Name | Age | Since | Title |
---|---|---|---|
Waldemar Priebe | - | - | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board |
Robert E. George | 74 | 2016 | Independent Director |
Joy Yan | 44 | 2022 | Independent Director |
John Michael Climaco | 55 | 2017 | Lead Independent Director |
Walter V. Klemp | 64 | 2015 | Founder, Chairman, President & CEO |
Michael D. Cannon | 79 | 2016 | Independent Director |
Elizabeth A. Cermak | 66 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review